Epizyme, Inc. (EPZM)

Oncology Corporate Profile

Stock Performance

11.1600
0.1300

HQ Location

400 Technology Square 4th Floor
Cambridge, MA 2139

Company Description

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression.

Website: http://www.epizyme.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tazemetostatEZH2 inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
EPZ-6438EZH2 inhibitorNon-Hodgkin's Lymphoma (NHL)II
tazemetostatEZH2 inhibitorSarcomaII
EPZ-5676DOT1L inhibitorAcute Myelogenous Leukemia (AML)I

View additional information on product candidates here »

Source: http://www.epizyme.com

Recent News Headlines

5/29/2017 06:17 pm

5/29/2017 06:17 pm

5/29/2017 06:17 pm

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/18/2017 06:17 am

5/18/2017 06:17 am

5/18/2017 06:17 am

5/18/2017 06:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/17/2017 06:17 am

5/17/2017 06:17 am

5/10/2017 06:18 am

5/9/2017 06:17 am

5/8/2017 12:17 am

5/8/2017 12:17 am

5/5/2017 06:18 am

5/4/2017 12:17 am

5/4/2017 12:17 am